Geneva – The World Health Organization (WHO) has issued conditional recommendations for the use of GLP-1 receptor agonist drugs – initially developed for diabetes – in the long-term treatment of obesity among adults, excluding pregnant women. The declaration, made today, acknowledges the potential of these treatments too combat a growing global health crisis, but stresses they are not a “solution miracle.”
according to the WHO, these drugs can help millions overcome obesity and reduce associated risks like type 2 diabetes, heart disease, and certain cancers. Though, the recommendation is “conditional” due to the need for further data regarding long-term effectiveness and safety.
“We cannot consider these drugs as a miracle solution,” stated Jeremy Farrar, WHO Assistant Director-General for Health Promotion, Disease Prevention and Control. “But they will clearly become a very important element of an integrated approach to obesity.”
The WHO emphasizes that medication alone is insufficient. Intensive behavioral interventions,including healthy eating and increased physical activity,are crucial alongside drug treatment. The organization also calls for “robust policies” to promote health, prevent obesity, and implement targeted screening for high-risk individuals.
Francesca Celletti, WHO senior advisor on obesity, noted the potential to “change this epidemiological trajectory of obesity,” but warned that without intervention, global costs related to overweight and obesity are projected to reach $3 trillion annually by 2030. She also acknowledged “current production capacity is insufficient,” raising concerns about access, notably in lower-income countries, and shortages experienced by diabetic patients for whom the drugs were originally intended. The WHO hopes the new guidelines will spur the development of cheaper generic versions and local production.
